BioSpectrum the business of Bio & Health Sciences
ASIA EDITION

Apollo Pharmacy cautions against Ranbaxy drugs' use

10 June 2013 | News | By BioSpectrum Bureau

New Delhi: Spelling further problems for India's pharma giant Ranbaxy and its Japanese owners Daiichi Sankyo, Apollo Pharmacy has issued a 'cautionary advisory' against the use of all drugs manufactured by Ranbaxy.

India's biggest branded drug retail network, Apollo Pharmacy, has more than 1,500 outlets in the country. it said in a press statement that their advisory was issued based on concerns raised by their medical committee.

"We have been working closely with Ranbaxy over the past week to verify all necessary certifications of their drugs," a spokesperson said in the statement. Adding that the issue was being resolved as Ranbaxy has been providing all the necessary paperwork.

The pharma giant had in May this year pleaded guilty on felony charges by US Food and Drug Administration (FDA) and US Department of Justice (DOJ), for selling adulterated drugs in the American market, had made a settlement of $500 million.

Reacting to this advisory issued by Apollo, Ranbaxy spokesperson told the Press Trust of India (PTI), "We have met the CEO of Apollo Pharmacy and they have expressed complete trust on us and assured full support. Consultants continue to prescribe our products and we have continuous supply of our products in Apollo Hospitals."